

Amendments to the Claims

1.-22. **(Cancelled)**

23. **(Currently Amended)** An isolated neuropilin binder (NPB), wherein the NPB is a monoclonal antibody, or antigen binding fragment thereof, that specifically binds to cell surface neuropilin-1 and inhibits angiogenesis of a cell expressing neuropilin-1 without inhibiting the binding of VEGF165 to neuropilin-1.

24. **(Previously Presented)** The NPB of claim 23, comprising the sequence set forth in SEQ ID No.: 15.

25. **(Previously Presented)** The NPB of claim 23, comprising a VH domain comprising amino acid residues 1 to 116 of the sequence set forth in SEQ ID No.: 15.

26. **(Previously Presented)** The NPB of claim 23, comprising a VL domain comprising amino acid residues 134 to 243 of the sequence set forth in SEQ ID No.: 15.

27. **(Previously Presented)** The NPB of claim 23, comprising a VH domain comprising CDR 1, 2 and 3 regions comprising amino acid residues 16 to 22, 40 to 56, and 89 to 105 respectively of the sequence set forth in SEQ ID No.: 15.

28. **(Previously Presented)** The NPB of claim 23, comprising a VL domain comprising CDR 1, 2 and 3 regions comprising amino acid residues 157 to 168, 184 to 190, and 222 to 232 respectively of the sequence set forth in SEQ ID No.: 15.

29. **(Previously Presented)** An isolated NPB, wherein the NPB is a monoclonal antibody, or antigen binding fragment thereof, that competes for binding to neuropilin-1 with the NPB claim 24.

30. **(Currently Amended)** A composition comprising the NPB according to any one of claims 23, 24, 25, 26, 27, 28, or 29 ~~of claim 23~~, and a pharmaceutically acceptable carrier.

31. **(Currently Amended; Withdrawn)** A method of treating or preventing cancer or metastasis in a patient, the method comprising administering to the patient the NPB according to any one of claims 24, 25, 26, 27, 28, or 29 ~~claim 23 or the composition according to claim 30~~ in an amount effective to inhibit neuropilin-1 mediated invasion and/or adhesion.